This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: The General Hosptial Corporation. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: Arda Mizrak: Innovator in RNA Targeting Technologies
Introduction
Arda Mizrak is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of molecular biology, particularly in the area of RNA targeting technologies. His innovative work has the potential to impact therapeutic applications significantly.
Latest Patents
Mizrak holds a patent for "Targeting RNAs to microvesicles." This patent discloses an isolated nucleic acid molecule comprising a specific nucleic acid sequence, operably linked to a second, heterologous nucleic acid sequence. The isolated nucleic acid molecule can be either DNA in an expression vector or RNA, including mRNA, shRNA, or ncRNA. The patent also describes a microvesicle that comprises the nucleic acid molecule and a method for producing a microvesicle preparation enriched for a specific RNA sequence by transfecting cells with the nucleic acid sequence. Furthermore, it outlines methods for delivering therapeutic RNA to a subject.
Career Highlights
Arda Mizrak is associated with The General Hospital Corporation, where he continues to advance his research and development efforts. His work is characterized by a commitment to innovation and excellence in the field of biotechnology.
Collaborations
Mizrak has collaborated with notable colleagues, including Okay Saydam and Mehmet Fatih Bolukbasi. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries.
Conclusion
Arda Mizrak is a key figure in the field of RNA targeting technologies, with a patent that showcases his innovative approach to molecular biology. His contributions are paving the way for future advancements in therapeutic applications.